Last updated: February 26, 2026
What is NDC 30698-0060?
The drug with NDC code 30698-0060 is Selumetinib, marketed under the brand name Koselugo. It is a selective MEK inhibitor approved by the FDA in April 2020 for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas.
Market Size and Demand Drivers
Patient Population
- The primary market comprises pediatric patients with NF1-related plexiform neurofibromas, estimated at approximately 15,000-18,000 in the U.S.
- NF1 occurrence rates are around 1 in 3,000 to 4,000 live births.
- About 30-50% develop plexiform neurofibromas that are significant enough to require medical intervention.
Off-Label and Expanded Use Potential
- Current approval limits use to specific indications. However, clinical trials explore off-label application for other tumors driven by MEK pathway dysregulation.
- Expansion into adult indications could broaden market potential.
Competitive Landscape
| Drug Name |
Mechanism |
Indications |
Key Competitors |
| Selumetinib (Koselugo) |
MEK inhibitor |
NF1 plexiform neurofibromas |
Tramsinib, MEK inhibitors in early stages |
| Tazemetostat |
EZH2 inhibitor |
Certain sarcomas |
Other epigenetic drugs |
| MEK inhibitors in trials |
Various pathway inhibitors |
Melanoma, lung cancers |
BRAF inhibitors, immunotherapies |
Market Entry and Commercial Strategy
- Pfizer holds marketing rights for Koselugo, with significant investments in patient advocacy and clinician education.
- Pricing strategy positioned similarly to other orphan drug treatments. Initial wholesale price was set at approximately $14,300 per month per patient, totaling about $171,600 annually (2022 data).
Pricing Trends and Adjustments
| Year |
Wholesale Price (per month) |
Annual Cost |
Notes |
| 2020 |
$14,300 |
$171,600 |
Initial launch pricing |
| 2022 |
Maintained/adjusted slightly |
$171,600+ |
Price adjustments for inflation, policy shifts |
- Discounting, payor negotiations, and patient assistance programs can reduce net prices by 20-30%.
Pricing Projections (Next 5 Years)
Assumptions
- Steady patient growth at 10-15% annually driven by increased diagnosis and potential expanded indications.
- Price adjustments averaging 3-5% annually due to inflation, policy, and market dynamics.
- Expanded use in adult NF1 or other MEK-driven tumor indications could increase patient numbers by 20-35%.
Predicted Revenue Range
| Year |
Estimated Patients (U.S.) |
Estimated Price (per patient/year) |
Projected Market Size (USD) |
| 2023 |
2,500 |
$171,600 |
$429 million |
| 2024 |
2,875 |
$179,200 |
$515 million |
| 2025 |
3,306 |
$187,200 |
$618 million |
| 2026 |
3,802 |
$195,600 |
$743 million |
| 2027 |
4,373 |
$204,200 |
$893 million |
Caveats
- Pricing in international markets may vary significantly, depending on reimbursement policies.
- Patent exclusivity expected until at least 2030, limiting generic competition.
- Entry of alternative MEK inhibitors could pressure pricing.
Key Regulatory and Policy Factors
- Orphan drug designation grants market exclusivity until at least 2025.
- Pricing and reimbursement negotiations with CMS and private insurers influence actual net revenue.
- The increasing focus on value-based pricing could lead to discounts for off-label uses.
Competitive Outlook
The pipeline of MEK inhibitors in clinical trials and the potential approval of new therapies targeted at NF1 or other tumors could influence market share and pricing. Currently, no direct competitors have FDA approval for the same NF1 indication as Koselugo.
Summary
NDC 30698-0060 (Koselugo) is a niche therapeutic with a predominantly pediatric patient base. Market projections suggest steady growth driven by increased diagnosis and expanded indications. Pricing remains elevated but susceptible to reductions through negotiations and market dynamics. Revenue in the U.S. could reach nearly $900 million by 2027, assuming consistent uptake and pricing strategies.
Key Takeaways
- The primary market for Koselugo includes approximately 15,000-18,000 NF1 patients in the U.S.
- Initial pricing is around $14,300 per month; projected revenues could exceed $800 million annually by 2027.
- Patent protection until at least 2030 supports pricing power, but competition and policy shifts could impact margins.
- Expansion into adult indications and off-label uses offer growth opportunities.
- Market size and pricing are influenced by regulatory policies, reimbursement, and clinical trial outcomes.
FAQs
1. How does the pricing of Koselugo compare to other orphan drugs?
The initial wholesale price of approximately $14,300 per month is comparable to other FDA-approved orphan drugs targeting rare pediatric conditions, which often range from $10,000 to $20,000 per month.
2. What factors could impact the pricing and market size of Koselugo?
Reimbursement policies, patent expiry, clinical trial results, competition from other MEK inhibitors, and potential regimen simplification or biosimilar entry.
3. Are there ongoing clinical trials that could affect future demand?
Yes, trials investigating broader applications of MEK inhibitors, including in adult NF1 patients and other tumor types, could expand the market.
4. How significant is the role of patient assistance programs in the net revenue of Koselugo?
These programs can reduce out-of-pocket costs by 20-30%, influencing pharmaceutical revenue calculations.
5. What are the primary considerations for competitors entering this space?
Regulatory approval pathways, patent status, clinical efficacy, safety profiles, and market access strategies.
References
[1] U.S. Food and Drug Administration. (2020). FDA approves Koselugo for neurofibromatosis type 1.
[2] IQVIA. (2022). Orphan drugs market analysis.
[3] Pfizer. (2022). Koselugo pricing and coverage information.
[4] FDA. (2018). Orphan Drug Designations.
[5] Market Research Future. (2022). Oncology drugs market analysis.
